Author(s):
Achmad Chusnu Romdhoni, Jordan Fahmi, Achmad Januar Er Putra, Ibrahim Syamsuri, Ulinta Purwati Pasaribu
Email(s):
romdhoni-a-c@fk.unair.ac.id
DOI:
10.52711/0974-360X.2024.00559 
Address:
Achmad Chusnu Romdhoni1*, Jordan Fahmi2, Achmad Januar Er Putra2, Ibrahim Syamsuri2, Ulinta Purwati Pasaribu3
1Department of Otorhinolaryngology - Head and Neck Surgery, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
2Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
3Radiotherapy Installation, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
*Corresponding Author
Published In:
Volume - 17,
Issue - 8,
Year - 2024
ABSTRACT:
We present a particular case in which nimotuzumab usage as the chemotherapy for locoregionally advanced NPC gives a better outcome for the patient. A 52-year-old woman came with a history of left side stuffiness, rhinorrhea, epistaxis, and hearing loss since 1.5 years ago. She complained about intracranial symptoms such as headaches, tingling sensation, diplopia, and strabismus on the left side of the face for one year before admission. Biopsy of the nasal cavity in July 2018 showed undifferentiated non-keratinizing carcinoma. CT scan showed a mass in the nasopharyngeal cavity without intracranial extension. A pre-therapeutic CT scan in October 2019 showed a massive intracranial extension with midline shift and perifocal edema. She was diagnosed with stage 4a nasopharyngeal carcinoma. The patient received a combination of 35 times radiotherapy and five times administration of Nimotuzumab. A post-therapeutic CT scan showed a loss of nasopharyngeal mass and intracranial sign. The treatment has improved all symptoms with negligible side effects, and Karnofsky's score is as high as 90. Nimotuzumab showed to give negligible toxicity and is well-tolerated among locally advanced NPC patients. The appropriation of Nimotuzumab in locally advanced NPC with intracranial infiltration was tolerable and showed convincing clinical results.
Cite this article:
Achmad Chusnu Romdhoni, Jordan Fahmi, Achmad Januar Er Putra, Ibrahim Syamsuri, Ulinta Purwati Pasaribu. Combination of Radiotherapy and Nimotuzumab for Locally Advanced Nasopharyngeal Carcinoma: A Case Report. Research Journal of Pharmacy and Technology. 2024; 17(8):3582-6. doi: 10.52711/0974-360X.2024.00559
Cite(Electronic):
Achmad Chusnu Romdhoni, Jordan Fahmi, Achmad Januar Er Putra, Ibrahim Syamsuri, Ulinta Purwati Pasaribu. Combination of Radiotherapy and Nimotuzumab for Locally Advanced Nasopharyngeal Carcinoma: A Case Report. Research Journal of Pharmacy and Technology. 2024; 17(8):3582-6. doi: 10.52711/0974-360X.2024.00559 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-8-7
REFERENCES:
1. Abdel Khalek Abdel Razek A, King A. MRI and CT of nasopharyngeal carcinoma. AJR Am J Roentgenol. 2012; 198(1): 11–8.
2. Lang J, Hu C, Lu T, Pan J, Lin T. Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives. Cancer Manag Res. 2019; 11: 6365.
3. Salehiniya H, Mohammadian M, Mohammadian-Hafshejani A, Mahdavifar N. Nasopharyngeal cancer in the world: epidemiology, incidence, mortality and risk factors. World Cancer Res J. 2018; 5(1): 1–8.
4. World Health Organization. Cancer Incident in Indonesia. Int Agency Res Cancer. 2020; 858: 1–2.
5. Huang J, Zou Q, Qian D, Zhou L, Yang B, Chu J, et al. Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma. Onco Targets Ther. 2017; Volume 10: 5835–41. doi:10.2147/OTT.S151554.
6. Xu S, Ramos-Suzarte M, Bai X, Xu B. Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget; Vol 7, No 22. 2016;
7. Subash VK, Radha S, Thatikonda S, Rao AY, Prakash CSK. Nail toxicity induced by cancer chemotherapy patients: data from the two multispecialty hospital. Res J Pharm Technol. 2015; 8(1): 20–6.
8. Saha D, Mridha D, Mondal S, Jana M, Kayal S. Organoselenium as a Cancer Chemopreventive Agent against Carcinogenesis. Res J Pharm Technol. 2011; 4(3): 367–8.
9. Yuan JJ, Ding JW, Li JW, Hu RH, Gong D, Hu JL, et al. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial. BMJ Open. 2022; 12(8): e051594. doi:10.1136/bmjopen-2021-051594.
10. Li HM, Li P, Qian YJ, Wu X, Xie L, Wang F, et al. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma. BMC Cancer. 2016; 16(1): 946.
11. Kamal N, Ilowefah MA, Hilles AR, Anua NA, Awin T, Alshwyeh HA, et al. Genesis and Mechanism of Some Cancer Types and an Overview on the Role of Diet and Nutrition in Cancer Prevention. Molecules. 2022; 27(6). doi:10.3390/molecules27061794.
12. Chan EWC, Wong SK. Corosolic acid: A synopsis on its anticancer properties. Asian J Pharm Clin Res. 2018; 11(9): 32–6. doi:10.22159/ajpcr.2018.v11i10.27696.
13. How CW, Teoh SL, Loh JS, Tan SLK, Foo JB, Ng HS, et al. Emerging Nanotheranostics for 5-Fluorouracil in Cancer Therapy: A Systematic Review on Efficacy, Safety, and Diagnostic Capability. Front Pharmacol. 2022; 13. doi:10.3389/fphar.2022.882704.
14. RA Hajare, KS Parwani, SA Bajad, NA. Chandekar Avc. Breast Cancer and Indole -3-Carbinol: Controversy of Estrogen Level and Enzyme Elastase. Res J Pharm Technol. 2009; 2(3): 439–40.
15. 3Ying H, Zhai R, Du C, Huang S, Kong F, Hu C, et al. Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Onco Targets Ther. 2015; 8: 3383. doi:10.2147/OTT.S93238.
16. Fei Z, Xu T, Li M, Chen T, Li L, Qiu X, et al. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol. 2020; 15(1): 230. doi:10.1186/s13014-020-01674-5.
17. Mohamed B, Amine M, Yassine H, Meriem D, Sami R, Reda A, et al. Undifferentiated nasopharyngeal cancer extending to maxillary sinus: a case report. PAMJ. 2020; 36(276).
18. Daker M, Lin VY, Akowuah GA, Cheng CN, Okechukwu PN. Anti-proliferative activity of standardized methanol extract of coscinium fenestratum and its major constituent, berberine, against nasopharyngeal carcinoma cells. Nat Prod J. 2013; 3(1): 42–51. doi:10.2174/2210315511303010009.
19. Verma M, Sheoran P, Chaudhury A. Application of nanotechnology for cancer treatment. Adv Anim Biotechnol its Appl. 2018; 161–78.
20. Kalpanapriya D, Saravanan M. Detection of breast cancer by ultrasonic image using wavelet transforms. Res J Pharm Technol. 2017; 10(3): 839–42.
21. Citrin DE, Mitchell JB. Altering the response to radiation: sensitizers and protectors. Semin Oncol. 2014/10/07. 2014; 41(6): 848–59.
22. Daker M, Lin VY, Akowuah GA, Yam MF, Ahmad M. Inhibitory effects of Cinnamomum burmannii Blume stem bark extract and trans-cinnamaldehyde on nasopharyngeal carcinoma cells; synergism with cisplatin. Exp Ther Med. 2013; 5(6): 1701–9. doi:10.3892/etm.2013.1041.
23. Suresh R, Benitojohnson D, Maheswari C, Venkatnarayanan R, Manavalan R. Chemo preventive activity of Triumfetta rhomboidea in 7, 12-dimethylbenz (A) anthracene induced breast cancer in Sprague-Dawley rat model. Res J Pharm Technol. 2017; 10(3): 687–92.
24. Asaad RA. Hormone receptor status and its relation to C-reactive protein and other prognostic factors in breast cancer in Jableh-Syria. Res J Pharm Technol. 2017; 10(9): 3003–10.
25. Hussein HH, Alsabari EK, Kadhim BA, Hatif KH, AL-Khafaji QS, Hamidi SAK. Study the Impact of the Trace Elements between the Healthy Females and who take Chemotherapy for samples of Sera. Res J Pharm Technol. 2017; 10(10): 3323–5.
26. Youssef L, Sara R, Mohamed E, Youssef R, Hassan N, Abdelaziz R. Choanal stenosis post radiotherapy for nasopharyngeal carcinoma: about an endoscopic management. PAMJ. 2019; 34(111).
27. Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18(7): 873–98.
28. Lee SK, Lee ZX, Lim YY, Liew KB, Akowuah GA, Chew YL. Ramie (Boehmeria nivea): A Functional Food and Herbal Medicine for Inflammatory Bowel Disease (IBD) and the Promotion of Optimal Health. Nat Prod J. 2022; 12(7). doi:10.2174/2210315512666220302160241.
29. Kentjono WA, Wardhani LK, Romdhoni AC. Association between dose and duration of cisplatin exposure with sitotoksisity effect on nasopharyngeal carcinoma stem cell. Indian J Forensic Med Toxicol. 2020; 14(2): 2364–8.
30. Li Z, Li Y, Yan S, Fu J, Zhou Q, Huang X, et al. Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma. Onco Targets Ther. 2017; 10: 5445–58.
31. Liang R, Yang L, Zhu X. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma. Cancer Control. 2021; 28(71): 1–6.
32. Swapnaa B, Kumar S V. Personalized medicine-A novel approach in cancer therapy. Res J Pharm Technol. 2017; 10(1): 341–5.
33. Liu ZG, Zhao Y, Tang J, Zhou YJ, Yang WJ, Qiu YF, et al. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget. 2016; 7(17): 24429–35.
34. Chauhan R, D’Souza HL, Shabnam RS, Abraham J. Phytochemical and cytotoxicity analysis of seeds and leaves of Adenanthera pavonina. Res J Pharm Technol. 2015; 8(2): 198–203.
35. Rathi MA, Meenakshi P, Kumar DG, Raj CA, Sunitha M, Gopalakrishnan VK. Leaves of Spermacoce hispida as a novel cancer therapeutic–An in vitro study. Res J Pharm Technol. 2011; 4(8): 1288–91.
36. Sachin J, Gupta NV. Solid lipid nanoparticles–preparation, applications, characterization, uses in various cancer therapies: a review. Res J Pharm Technol. 2013; 6(8): 825–37.
37. Wang BC, Shi LL, Fu C, Zhang ZJ, Ba L, Xiong Y, et al. Concurrent chemotherapy with or without nimotuzumab for treatment for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Int J Clin Exp Med. 2019; 12(8): 9998–10008.
38. Kokulwar PU, Lakhane KG, Mitkare SS. Microbubble Ultrasound: A Novel Approach in Cancer Therapy. Res J Pharm Technol. 2013; 6(11): 1279–84.